Vol. 4 No. 4 (2024)
Reimbursement Reviews

Ibrutinib (Imbruvica)

decorative image of the issue cover

Published April 2, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses ibrutinib (Imbruvica), 140 mg capsule, oral.
  • Indication: For the treatment of adult patients with:
    • Waldenström macroglobulinemia (WM) as a monotherapy or in combination with rituximab
    • Previously untreated active chronic lymphocytic leukemia (CLL), including patients with 17p deletion
    • CLL who received at least one prior therapy, in combination with bendamustine and rituximab
    • Relapsed or refractory mantle cell lymphoma (MCL)
    • marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy
    • Steroid-dependent or refractory chronic graft vs. host disease (cGVHD)